2015 American Transplant Congress
The Benefit of Hepatitis C Donor Kidney Transplantation Is Limited to Hepatitis C Positive Patients Over 50 Years of Age
Division of Nephrology, University of British Columbia, Vancouver, BC, Canada.
The purpose of this analysis was to provide information regarding the use and survival benefit of kidney transplantation from a hepatitis C positive deceased donor…2015 American Transplant Congress
Long-term Patient and Graft Survival After Kidney Transplantation in Recipients With Hepatitis C Virus Infection
Division of Gastroenterology and Hepatology, Stanford University, Stanford.
Background: The prevalence of hepatitis C virus (HCV) infection among kidney transplant (KTx) recipients is higher than that in the general population. With the advent…2015 American Transplant Congress
Combined Hepatitic/Cholangiopathic Lesion in HIV-HCV Co-Infected Liver Transplant Recipients Associated With Graft Loss
Background: Co-infection with HIV and viral hepatitis results in poorer outcomes following liver transplantation. In this population, complex immune status, extensive drug regimens, and comorbid…2015 American Transplant Congress
Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients
Purpose: HCV is the leading cause of end-stage liver disease, universally recurring in the post-transplant setting. Studies have shown disappointing results after first generation protease…2015 American Transplant Congress
HCV Treatment in Liver Transplantation: Changes in Center Attitudes and Practices in the DAA Era
Surgery, Johns Hopkins University, Baltimore, MD.
Chronic hepatitis C virus infection (HCV) is the leading indication for liver transplantation (LT) in the US. Safe and effective directly acting antivirals (DAAs) are…2015 American Transplant Congress
Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation
Purpose: Evaluate outcomes of sofosbuvir-based hepatitis C therapy in liver transplant patients in a single center clinical setting, including interferon-free regimens.Methods: All patients with history…2015 American Transplant Congress
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
BACKGROUND: The treatment of HCV is one of the most rapidly changing areas of medical practice. These agents have been shown to be safe and…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…2015 American Transplant Congress
Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience
Liver Institute, Methodist Dallas Medical Center, Dallas, TX.
Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is…2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…
American Transplant Congress abstracts